ID: ALA317426

Max Phase: Preclinical

Molecular Formula: C38H43N3O7

Molecular Weight: 653.78

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(C(CCN2CCN(c3ccccc3OC)CC2)Oc2ccc(C(=O)Nc3ccccc3OCCCC(=O)O)cc2)cc1

Standard InChI:  InChI=1S/C38H43N3O7/c1-45-30-17-13-28(14-18-30)34(21-22-40-23-25-41(26-24-40)33-9-4-6-11-36(33)46-2)48-31-19-15-29(16-20-31)38(44)39-32-8-3-5-10-35(32)47-27-7-12-37(42)43/h3-6,8-11,13-20,34H,7,12,21-27H2,1-2H3,(H,39,44)(H,42,43)

Standard InChI Key:  SWSPNKVLDQNLHI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 653.78

Molecular Weight (Monoisotopic): 653.3101

AlogP: 6.53

#Rotatable Bonds: 16

Polar Surface Area: 109.80

Molecular Species: ACID

HBA: 8

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 10

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.90

CX Basic pKa: 7.84

CX LogP: 3.31

CX LogD: 3.21

Aromatic Rings: 4

Heavy Atoms: 48

QED Weighted: 0.13

Np Likeness Score: -0.92

References

1. Yoshida K, Horikoshi Y, Eta M, Chikazawa J, Ogishima M, Fukuda Y, Sato H..  (1998)  Synthesis of benzanilide derivatives as dual acting agents with alpha 1-adrenoceptor antagonistic action and steroid 5-alpha reductase inhibitory activity.,  8  (21): [PMID:9873656] [10.1016/s0960-894x(98)00538-1]

Source

Source(1):

• Scientific Literature